Abstract:Introduction: Micro-RNAs (miRNAs) are 19-24 nucleotide non-coding RNAs that regulate gene expression through the inactivation of their messenger RNA. Previous studies have demonstrated the important role of some miRNAs in the development of cancer. Specifically, in diffuse large B cell lymphoma (DLBCL), miRNAs involved in lymphomagenesis were identified but understanding their biological function continues to be a challenge. Nevertheless, the pathogenesis effects of some miRNAs such as miR-125a, miR-17-92 cluster or mi-R-155 are well characterized. Some studies suggest that miRNAs also possess a prognostic potential role in DLBCL. For this reason, our objective was to analyze the different miRNAs involved in the chemo-sensitivity or resistance to the first line treatment, their correlation with standard prognostic factors at diagnosis and the role of these miRNAs in survival in patients with DLBCL. Material and methods: Patients homogeneously treated with R-CHOP from 1999-2013 were reviewed from 3 Spanish centers. They were retrospectively obtained from Pathology Department registry to avoid selection bias. We included those patients with valid genomic material in formalin-fixed-paraffin-embedded tissue and with available clinical data. Samples were processed using the miRNA 4 Affymetrix microarrays kit in a discovery group that included 2 cohorts (patients with durable complete remission (CR) versus refractory or early relapsing patients). Those miRNAs with differential expression were validated in the whole series with quantitative RT-PCR. We also analyzed the role of these miRNAs as predictors of event-free survival (EFS) and overall survival (OS) and their relationship with standard prognostic factors in DLBCL. Results: We identified 156 patients homogeneously treated with R-CHOP. Finally, 96 samples were obtained with valid material for RNA extraction. To identify those miRNAs with prognostic implication, a discovery cohort of 12 patients was used in which all the cases had poor prognosis with high tumor load and advance disease (III-IV stage and unfavorable R-IPI). On this basis of poor prognosis, 2 groups were defined totally opposed from the point of view of the treatment response and evolution: chemo-resistance group (n=6) including refractory or relapsed (RR) patients (first 12 months) and chemo-sensitive group (n=6) including patients with at least 3 years of CR. A hierarchical clustering was performed in which 26 miRNAs differentially expressed were identified. A screening of miRNAs was carried out based on the fold-change and pathways involved and finally we obtained 10 miRNAs differentially expressed in RR group. The validation of these miRNAs was performed with quantitative RT-PCR in the whole series which finally included 68 samples with valid material. A univariate survival analysis including clinical prognostic factors and the selected 10 miRNAs was performed. We confirmed that 7 of them (miR-20b-5p, miR-1244, miR-6840-3p, miR-1231, miR-193b-5p, miR-6860-5p y miR-199a-5p) significantly influenced EFS and 6 of them (miR-1244, miR-1231, miR-193b-5p, miR-885-3p, miR-182-5p y miR-199a-5p) on OS. From these 10 miRNAs, only 3 had a significant prognosis role not only for EFS but also for OS and progression-free survival (PFS): miR-1244, miR-193b-5p and miR-1231. The overexpression of miR-1244 and miR-193-5p were associated with advance stage and worse clinical prognosis factors (p 15% were independently associated with worse SG and EFS (Figure 1). In previously reported studies, these 3 miRNAs have been related with proliferative events such as the overexpression of myc or anti-apoptosis. Also, the miR-1231 may be related with new lymphomagenesis pathways associated to viral infections. Conclusions: Through a discovery group focused on progression/refractoriness, a group of new miRNAs differentially expressed on chemo-resistant patients with DLBCL was identified. The overexpression of miR-1244 and miR-193-5p was associated with more extensive disease and worse clinical prognostic factors. The high R-IPI, reduction of >15% RDI and the overexpression of miR-1231 were independently associated with worse EFS and OS. Disclosures Sánchez-González: Amgen: Consultancy, Speakers Bureau; Gilead: Speakers Bureau; Navartis: Consultancy, Speakers Bureau; Shire: Speakers Bureau; Takeda: Consultancy, Speakers Bureau. Salar:Roche: Research Funding, Speakers Bureau; Janssen Pharmaceuticals: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Celgene: Consultancy.

Deregulated Expression of Mir-224 and Its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP.

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: a Report from the International DLBCL Rituximab-CHOP Consortium Program.

Expression of miR-224 in diffuse large B cell lymphoma and its clinical significance]

Rituximab-CHOP Consortium Program demonstrates high-risk gene expression signatures : a report from The activated B-cell subtype of diffuse large B-cell lymphoma and MYC / BCL 2 protein coexpression contributes to the inferior survival of

Low Expression of Microrna-146B-5p and Microrna-320D Predicts Poor Outcome of Large B-cell Lymphoma Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

MicroRNAs Are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma

Prognostic Significance of MiRNA in Patients with Diffuse Large B-Cell Lymphoma: a Meta-Analysis

Clinical and Prognostic Significance of Mir-155 and Mir-146A Expression Levels in Formalin-Fixed/paraffin-embedded Tissue of Patients with Diffuse Large B-cell Lymphoma.

Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients

Increased CD59 Protein Expression is Associated with the Outcome of Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP

High Expression of Mir-25 Predicts Favorable Chemotherapy Outcome in Patients with Acute Myeloid Leukemia.

A Novel Circulating 4-Mirna Prognostic Model in Diffuse Large B-Cell Lymphoma: Role of MDSCs and Th17 Cells on Lymphoma Progression

Analysis of Micro-RNAs Associated to Treatment Failure in Diffuse Large B Cell Lymphoma

Expression of MiR-296-5p in Diffuse Large B-Cell Lymphoma and Its Influence on Biological Behavior of Tumor Cells

Serum Microrna Prognostic Model and Underlying Immune Alterations in Diffuse Large B Cell Lymphoma

Global Microrna Expression Profiling Uncovers Molecular Markers for Classification and Prognosis in Aggressive B-cell Lymphoma.

New Insights into MicroRNAs Involves in Drug Resistance in Diffuse Large B Cell Lymphoma.

Screening and Identification of Differentially Expressed Micrornas in Diffuse Large B-cell Lymphoma Based on Microrna Microarray.

A Novel Prognostic Model Based on Four Circulating Mirna in Diffuse Large B‐cell Lymphoma: Implications for the Roles of MDSC and Th17 Cells in Lymphoma Progression

[Expression of MiRNA-21 in Diffuse Large B Cell Lymphoma and Its Significance].